Magnus Ingelman-Sundberg
Overview
Explore the profile of Magnus Ingelman-Sundberg including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
271
Citations
7600
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dusek J, Mejdrova I, Dohnalova K, Smutny T, Chalupsky K, Krutakova M, et al.
Nat Commun
. 2025 Feb;
16(1):1418.
PMID: 39915454
Constitutive androstane receptor (CAR) and pregnane X receptor (PXR) are closely related nuclear receptors with overlapping regulatory functions in xenobiotic clearance but distinct roles in endobiotic metabolism. Car activation has...
2.
van Westrhenen R, Young A, Heilbronner U, Juruena M, Ingelman-Sundberg M, Jukic M, et al.
World Psychiatry
. 2025 Jan;
24(1):141-142.
PMID: 39810666
No abstract available.
3.
Weitzberg E, Ingelman-Sundberg M, Lundberg J, Engberg G, Schulte G, Lauschke V
Pharmacol Rev
. 2024 Oct;
76(6):1089-1101.
PMID: 39414365
Karolinska Institutet is a medical university encompassing 21 departments distributed across three departmental or campus groups. Pharmacological research has a long and successful tradition at the institute with a multitude...
4.
Milosavljevic F, Manojlovic M, Matkovic L, Molden E, Ingelman-Sundberg M, Leucht S, et al.
JAMA Netw Open
. 2024 Aug;
7(8):e2425593.
PMID: 39115847
Importance: Precise estimation of a patient's drug metabolism capacity is important for antiseizure dose personalization. Objective: To quantify the differences in plasma concentrations for antiseizure drugs associated with variants of...
5.
Ingelman-Sundberg M
Clin Pharmacol Ther
. 2024 Aug;
116(4):899-901.
PMID: 39101255
No abstract available.
6.
Storset E, Braten L, Ingelman-Sundberg M, Johansson I, Molden E, Kringen M
Eur J Clin Pharmacol
. 2024 Jul;
80(10):1531-1541.
PMID: 38963454
Purpose: The CYP2D6 gene exhibits significant polymorphism, contributing to variability in responses to drugs metabolized by CYP2D6. While CYP2D6*2 and CYP2D6*35 are presently designated as alleles encoding normal metabolism, this...
7.
van Westrhenen R, Ingelman-Sundberg M
Eur Neuropsychopharmacol
. 2024 Apr;
84:16-17.
PMID: 38643694
No abstract available.
8.
Ingelman-Sundberg M, Lauschke V
Drug Metab Dispos
. 2024 Apr;
52(6):467-475.
PMID: 38575185
In the area of drug development and clinical pharmacotherapy, a profound understanding of the pharmacokinetics and potential adverse reactions associated with the drug under investigation is paramount. Essential to this...
9.
Ingelman-Sundberg M, Molden E
Br J Clin Pharmacol
. 2024 Mar;
PMID: 38523083
Pharmacokinetics plays a central role in understanding the significant interindividual differences that exist in drug metabolism and response. Effectively addressing these differences requires a multi-faceted approach that encompasses a variety...
10.
Smith R, Wollmann B, Storset E, Lenk H, OConnell K, Kristiansen M, et al.
Clin Transl Sci
. 2024 Feb;
17(2):e13743.
PMID: 38385986
Cytochrome P450 2D6 (CYP2D6) is important for metabolism of 20%-25% of all clinically used drugs. Many known genetic variants contribute to the large interindividual variability in CYP2D6 metabolism, but much...